See more : Kingworld Medicines Group Limited (1110.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Edgewise Therapeutics, Inc. (EWTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edgewise Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) Income Statement Analysis – Financial Results
- PT Indo Komoditi Korpora Tbk (INCF.JK) Income Statement Analysis – Financial Results
- CM Life Sciences, Inc. (CMLFU) Income Statement Analysis – Financial Results
- Tian Shan Development (Holding) Limited (2118.HK) Income Statement Analysis – Financial Results
- Gold Port Corporation (GPOTF) Income Statement Analysis – Financial Results
Edgewise Therapeutics, Inc. (EWTX)
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.73M | 538.00K | 272.00K | 185.00K | 123.00K |
| Gross Profit | -1.73M | -538.00K | -272.00K | -185.00K | -123.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 90.91M | 16.61M | 32.19M | 14.98M | 8.62M |
| General & Administrative | 23.45M | 5.47M | 11.03M | 2.21M | 1.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.45M | 5.47M | 11.03M | 2.21M | 1.30M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 114.36M | 22.08M | 43.22M | 17.19M | 9.92M |
| Cost & Expenses | 114.36M | 22.08M | 43.22M | 17.19M | 9.92M |
| Interest Income | 14.19M | 2.66M | 402.00K | 69.00K | 219.00K |
| Interest Expense | 0.00 | 4.02M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.73M | 538.00K | 272.00K | 185.00K | 123.00K |
| EBITDA | -112.81M | -67.10M | -42.94M | -17.01M | -9.80M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -114.36M | -22.08M | -43.22M | -17.19M | -9.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 14.19M | 4.02M | 402.00K | 69.00K | 219.00K |
| Income Before Tax | -100.16M | -19.42M | -42.81M | -17.12M | -9.71M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.02M | -674.00K | -69.00K | -219.00K |
| Net Income | -100.16M | -15.40M | -42.14M | -17.05M | -9.49M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| EPS Diluted | -1.57 | -0.29 | -0.85 | -0.35 | -0.19 |
| Weighted Avg Shares Out | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
| Weighted Avg Shares Out (Dil) | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company's relationship with Dr. Han Phan at Rare Disease Research. On November 27, 2024, the U.S. Food and Drug Administration (FDA) issued...
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET. The presentation will be...
Analysts Think There's Still Time To Get In On Edgewise
Edgewise Therapeutics EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.
Analyst Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors.
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials.
EWTX Stock Soars on Upbeat Efficacy Data From Cardiomyopathy Studies
Edgewise stock soars on positive data from an early-stage study and Part A of a mid-stage study of EDG-7500 in obstructive hypertrophic cardiomyopathy patients.
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
Edgewise's EDG-7500 shows promise as a treatment for hypertrophic cardiomyopathy. This market is currently underserved, largely because many heart drugs can cause other cardiac problems.
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
On Thursday, Edgewise Therapeutics Inc. EWTX released announced topline data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCM trial for obstructive hypertrophic cardiomyopathy.
Source: https://incomestatements.info
Category: Stock Reports